ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,783.00
0.00%
S&P ASX All Technology
3,113.80
0.00%
Brent Oil
84.495
0.37%
US Dollar vs AUD
1.50421
-0.05%
Bitcoin
61,039.53
-1.25%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Galapagos (GLPG) Share Price

Galapagos

Galapagos (GLPG)

Galapagos NV
23.40
-0.64
(-2.66%)
Closed 27 June 1:30AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
23.40
Bid
23.40
Offer
23.46
Volume
98,719
23.40 Day's Range 24.04
23.40 52 Week Range 40.26
Market Cap
1.542B
Previous Close
24.04
Open
24.00
Last Trade
44
@
23.4
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
85,376
Shares Outstanding
65,897,000
Dividend Yield
-
PE Ratio
7.28
Earnings Per Share (EPS)
3.21
Revenue
843.8M
Net Profit
211.7M

About Galapagos

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
www.glpg.com
Headquarters
Mechelen, Antwerp, Bel
Founded
1970
Galapagos is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker GLPG. The last closing price for Galapagos was 24.04 €. Over the last year, Galapagos shares have traded in a share price range of 23.40 € to 40.26 €.

Galapagos currently has 65,897,000 shares in issue. The market capitalisation of Galapagos is 1.54 € billion. Galapagos has a price to earnings ratio (PE ratio) of 7.28.

GLPG Latest News

More News

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ:...

15 June 2024
GlobeNewswire Inc.

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and...

31 May 2024
GlobeNewswire Inc.

Galapagos creates new subscription right plans

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights...

17 May 2024
GlobeNewswire Inc.

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. BCA's national network of blood centers...

16 May 2024
GlobeNewswire Inc.

Galapagos reports first quarter 2024 financial results  

Galapagos reports first quarter 2024 financial results   Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15...

03 May 2024
GlobeNewswire Inc.

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’...

01 May 2024
GlobeNewswire Inc.

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation...

05 April 2024
GlobeNewswire Inc.

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary...

29 March 2024
GlobeNewswire Inc.
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.66-2.7431421446424.0624.6423.46600924.16616395DE
4-1.68-6.698564593325.082623.48893524.46276498DE
12-6.14-20.785375761729.5429.6623.48537626.32501468DE
26-13.05-35.802469135836.453923.48406230.37967889DE
52-13.92-37.299035369837.3240.2623.48610432.94020773DE
156-36.9-61.194029850760.366.2823.420304645.72083646DE
260-88.1-79.0134529148111.5252.923.4325324102.9476369DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
1ADAdAlta Limited
AUD 0.026
(0.00%)
0
14DO1414 Degrees Limited
AUD 0.008
(0.00%)
0
14DN1414 Degrees Limited
AUD 0.00
(0.00%)
0
14D1414 Degrees Limited
AUD 0.062
(0.00%)
0
13S13 Seeds Limited
 0.00
(0.00%)
0
1ADAdAlta Limited
AUD 0.026
(0.00%)
0
14DO1414 Degrees Limited
AUD 0.008
(0.00%)
0
14DN1414 Degrees Limited
AUD 0.00
(0.00%)
0
14D1414 Degrees Limited
AUD 0.062
(0.00%)
0
13S13 Seeds Limited
 0.00
(0.00%)
0
1ADAdAlta Limited
AUD 0.026
(0.00%)
0
14DO1414 Degrees Limited
AUD 0.008
(0.00%)
0
14DN1414 Degrees Limited
AUD 0.00
(0.00%)
0
14D1414 Degrees Limited
AUD 0.062
(0.00%)
0
13S13 Seeds Limited
 0.00
(0.00%)
0

Discussion

View Full Feed
stock1ace1 stock1ace1 5 minutes ago
*** VRNA Halted $14.60 Fda approval -> Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
VRNA
RobotDroid RobotDroid 5 minutes ago
They won't.
NWBO
PickStocks PickStocks 5 minutes ago
Doreen is a friend of yours…….lol
COOP
docsetc docsetc 5 minutes ago
Please be aware, ENZC has NO biotech to speak of at this moment. Zhabilov's ITV-1 failed toxicology tests and has been tossed into the back freezer as a shelf decoration. IPF-Immune also does not work. Clone3 and Clone7, and all other monoclonal antibody research material is over parked at the
ENZC
DewDiligence DewDiligence 5 minutes ago
CLF’s press conference today with Sen. Brown and USW President (29 minutes):

[yt]02pyWqyClFQ[/yt]
CLF
sprenkld sprenkld 5 minutes ago
From your mouth to the Stock God's ears...lolol.
SAPX
sprenkld sprenkld 5 minutes ago
From your mouth to the Stock God's ears...lolol.
SAPX
FCF2020 FCF2020 6 minutes ago
Tom Nash(CEO) is a total f up. Don't think anyone wants advice on how to bring their business to the bottom. Disruptive fintech? Nope.
XALL
Goulet57 Goulet57 6 minutes ago
On any and all of these message boards where people spend endless hours in their mothers’ basements trashing companies, you gotta ask yourself in each and every case, . . . why are they even here? There has to be good reason to drag them away from reruns of Gilligan’s Island and Dukes of Hazzard.
PPCB
monocle monocle 6 minutes ago
Due for green I guess, last was June 11th.

2 green days all of June in fact, 13 days red.

Without news, green tomorrow doesn't mean a whole lot.
NB
VeronicaFox VeronicaFox 6 minutes ago
Totally disagree, but It’s funny watching you trying to fit your entire vocabulary into one sentence.

$126 total volume.
KEGS
CatfishHunter CatfishHunter 6 minutes ago
Given the hand holding with FDA during this process and Mayo ramping up, I’m 95%+ confident in approval. No worries.
RDGL
Margin Buu Margin Buu 6 minutes ago
The timing of the approval announcement is in the hands of the regulators. Correct, and I’m fully expecting to see them approve DCVax-L any time within the next several weeks. 😎 No worries.
NWBO
SF971 SF971 6 minutes ago
Stocks like GTVH often see the biggest gains in pennyland, because they will say/do anything to attract interest.

The financier will make money for themselves and early investors.

Just remember, TK can't convert and sell and pay down the $4.6 M+ convertible debt unless
GTVH
mouton29 mouton29 7 minutes ago
Re: Eyepoint
the logic in quote i gave above is bizarre. It’s a stretch to say having 2 different dose arms mean that sham is ok?

FWIW (and that isn't much), I note that the sham injections in the Eyepoint phase 3 are of the type that this article (https://www.ncbi.nlm.nih.gov/
georgejjl georgejjl 7 minutes ago
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study

"...Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). D
AVXL
Denisk Denisk 7 minutes ago
why do you say$0.7218. I see $0.6982..
AMRN
IceCold8 IceCold8 8 minutes ago
Considering an r/s has occurred already with no result with the exception of the pps going down,what are the odds we have another reverse split?
AGSS
Carjockey2 Carjockey2 9 minutes ago
Boom

.50 AH
FFIE
quester614 quester614 9 minutes ago
I gave up counting the bags I carry. The risk reward in the OTC is worth the gamble. You play with the understanding you could LOSE everything. Which I have many times. BCJ I remember when I first stayed here posting what I thought about this SCAM. You condemn me then and still think I'm here to rai
XERI
WebSlinger WebSlinger 9 minutes ago
>

KBLB isn't anywhere near revenue.

The last PR said that they are breeding eggs in the next couple of months, and then will probably take a break because of "suboptimal rearing conditions".

No revenue in 2024 means more
KBLB
BurgerKing82 BurgerKing82 10 minutes ago
Yea,I wish I got in at 8 or 9
NNAX
lockstock31 lockstock31 10 minutes ago
Just ignore my posts. Age is catching up with me!
GTVH

Your Recent History

EU
GLPG
Galapagos
TG
0SJA
Rabobank Nederland
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved